Farouque H M Omar, Meredith Ian T
Cardiovascular Research Centre, Monash Medical Centre and Monash University, 246 Clayton Road, Clayton, Melbourne, Victoria 3168, Australia.
Clin Sci (Lond). 2003 Jan;104(1):39-46.
Experimental data suggest that vascular ATP-sensitive potassium (K(ATP)) channels may be an important determinant of functional hyperaemia, but the contribution of K(ATP) channels to exercise-induced hyperaemia in humans is unknown. Forearm blood flow was assessed in 39 healthy subjects (23 males/16 females; age 22+/-4 years) using the technique of venous occlusion plethysmography. Resting forearm blood flow and functional hyperaemic blood flow (FHBF) were measured before and after brachial artery infusion of the K(ATP) channel inhibitors glibenclamide (at two different doses: 15 and 100 microg/min) and gliclazide (at 300 microg/min). FHBF was induced by 2 min of non-ischaemic wrist flexion-extension exercise at 45 cycles/min. Compared with vehicle (isotonic saline), glibenclamide at either 15 microg/min or 100 microg/min did not significantly alter resting forearm blood flow or peak FHBF. The blood volume repaid at 1 and 5 min after exercise was not diminished by glibenclamide. Serum glucose was unchanged after glibenclamide, but plasma insulin rose by 36% (from 7.2+/-0.8 to 9.8+/-1.3 m-units/l; P =0.02) and 150% (from 9.1+/-1.3 to 22.9+/-3.5 m-units/l; P =0.002) after the 15 and 100 microg/min infusions respectively. Gliclazide also did not affect resting forearm blood flow, peak FHBF, or the blood volume repaid at 1 and 5 min after exercise, compared with vehicle (isotonic glucose). Gliclazide induced a 12% fall in serum glucose (P =0.009) and a 38% increase in plasma insulin (P =0.001). Thus inhibition of vascular K(ATP) channels with glibenclamide or gliclazide does not appear to affect resting forearm blood flow or FHBF in healthy humans. These findings suggest that vascular K(ATP) channels may not play an important role in regulating basal vascular tone or skeletal muscle metabolic vasodilation in the forearm of healthy human subjects.
实验数据表明,血管ATP敏感性钾(K(ATP))通道可能是功能性充血的一个重要决定因素,但K(ATP)通道对人类运动诱导性充血的作用尚不清楚。采用静脉阻断体积描记术对39名健康受试者(23名男性/16名女性;年龄22±4岁)的前臂血流量进行评估。在肱动脉输注K(ATP)通道抑制剂格列本脲(两种不同剂量:15和100微克/分钟)和格列齐特(300微克/分钟)前后,测量静息前臂血流量和功能性充血血流量(FHBF)。FHBF通过以45次/分钟进行2分钟的非缺血性腕关节屈伸运动诱导产生。与载体(等渗盐水)相比,15微克/分钟或100微克/分钟的格列本脲均未显著改变静息前臂血流量或FHBF峰值。运动后1分钟和5分钟时偿还的血容量未因格列本脲而减少。格列本脲给药后血清葡萄糖未发生变化,但血浆胰岛素在15微克/分钟和100微克/分钟输注后分别升高了36%(从7.2±0.8升至9.8±1.3 m单位/升;P=0.02)和150%(从9.1±1.3升至22.9±3.5 m单位/升;P=0.002)。与载体(等渗葡萄糖)相比,格列齐特也未影响静息前臂血流量、FHBF峰值或运动后1分钟和5分钟时偿还的血容量。格列齐特使血清葡萄糖下降了12%(P=0.009),血浆胰岛素增加了38%(P=0.001)。因此,用格列本脲或格列齐特抑制血管K(ATP)通道似乎不会影响健康人的静息前臂血流量或FHBF。这些发现表明,血管K(ATP)通道可能在调节健康人类受试者前臂的基础血管张力或骨骼肌代谢性血管舒张中不起重要作用。